| Serial Number | 99175610 |
| Word Mark | ON POINT |
| Filing Date | Thursday, May 8, 2025 |
| Status | 641 - NON-FINAL ACTION - MAILED |
| Status Date | Friday, October 17, 2025 |
| Registration Number | 0000000 |
| Registration Date | NOT AVAILABLE |
| Mark Drawing | 4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form |
| Published for Opposition Date | NOT AVAILABLE |
| Goods and Services | Custom manufacturing of oligonucleotide-conjugate based therapies, oligonucleotide-antibody conjugate based therapies, and oligonucleotide-antibody fragment conjugate based therapies; custom manufacturing of pharmaceuticals; contract manufacturing in the field of pharmaceuticals; providing technical information in the field of pharmaceutical manufacturing |
| Goods and Services | Medical and scientific research, namely, conducting clinical trials for others; providing medical and scientific research information in the fields of pharmaceuticals, biotechnology, and clinical trials; pharmaceutical research and development; pharmaceutical products development; research and development in the field of biotechnology |
| Goods and Services | Providing information in the fields of pharmaceuticals, therapeutics, healthcare, medicines, vaccines, health conditions, health awareness and treatment options; medical information services, namely, providing information related to healthcare, diseases, disorders, and treatment options; online information services, namely, providing a website related to healthcare, health awareness, medicines, vaccines, diseases, disorders, and treatment options |
| Goods and Services | Therapeutic pharmaceuticals in the nature of oligonucleotide-conjugate based therapies, oligonucleotide-antibody conjugate based therapies, and oligonucleotide-antibody fragment conjugate based therapies for the treatment of and prevention of musculoskeletal, neuromuscular, rare muscle diseases, cardiomyopathies, heart muscle diseases, muscular dystrophies, and muscle atrophy related diseases and disorders; pharmaceutical preparations for the treatment and prevention of viral, metabolic, endocrine, musculoskeletal, autoimmune, cardiovascular, cardiopulmonary, neuromuscular, rare muscle diseases, cardiomyopathies, heart muscle diseases, muscular dystrophies, muscle atrophy, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, neurodegenerative, gastrointestinal, hormonal, dermatological, psychiatric, genetic, and immune system related diseases and disorders; pharmaceutical preparations for the treatment and prevention of blood disorders, bone growth disorders, skin disorders, arthritis, cancer, hypertension, pain, stroke, obesity and diabetes; pharmaceutical preparations, namely, anti-infective preparations, medicated dermatological preparations and smoking cessation preparations; therapeutic pharmaceutical for the treatment and prevention of viral, metabolic, endocrine, musculoskeletal, autoimmune, cardiovascular, cardiopulmonary, neuromuscular, rare muscle diseases, cardiomyopathies, heart muscle diseases, muscular dystrophies, muscle atrophy, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, neurodegenerative, gastrointestinal, hormonal, dermatological, psychiatric, genetic, and immune system related diseases and disorders; therapeutic pharmaceuticals for the treatment and prevention of blood disorders, bone growth disorders, skin disorders, arthritis, cancer, hypertension, pain, stroke, obesity and diabetes |
| International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
| US Class Codes | 005, 006, 018, 044, 046, 051, 052 |
| Class Status Code | 6 - Active |
| Class Status Date | Thursday, May 8, 2025 |
| Primary Code | 005 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 040 - Treatment of materials. |
| US Class Codes | 100, 103, 106 |
| Class Status Code | 6 - Active |
| Class Status Date | Thursday, May 8, 2025 |
| Primary Code | 040 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software. |
| US Class Codes | 100, 101 |
| Class Status Code | 6 - Active |
| Class Status Date | Thursday, May 8, 2025 |
| Primary Code | 042 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 044 - Medical services; veterinary services; hygienic and beauty care for human beings or animals; agriculture, horticulture and forestry services. |
| US Class Codes | 100, 101 |
| Class Status Code | 6 - Active |
| Class Status Date | Thursday, May 8, 2025 |
| Primary Code | 044 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| Party Name | Avidity Biosciences, Inc. |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 03 - Corporation |
| Address | San Diego, CA 92121 |
| Event Date | Event Description |
| Thursday, May 8, 2025 | NEW APPLICATION ENTERED |
| Thursday, May 8, 2025 | APPLICATION FILING RECEIPT MAILED |
| Friday, September 5, 2025 | TEAS CHANGE OF OWNER ADDRESS RECEIVED |
| Friday, September 5, 2025 | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED |
| Friday, September 5, 2025 | TEAS CHANGE OF CORRESPONDENCE RECEIVED |
| Wednesday, September 17, 2025 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Wednesday, September 24, 2025 | ASSIGNED TO EXAMINER |
| Thursday, October 16, 2025 | ASSIGNED TO EXAMINER |
| Friday, October 17, 2025 | NON-FINAL ACTION WRITTEN |
| Friday, October 17, 2025 | NON-FINAL ACTION E-MAILED |
| Friday, October 17, 2025 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |